SGEN · Seagen Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $648.65M | $603.83M | $519.72M | - | $510.30M | $497.50M | $426.46M | - | $424.06M | $388.48M |
| Cost of Revenue | $165.25M | $180.75M | $111.78M | - | $108.12M | $106.10M | $87.63M | - | $82.65M | $78.09M |
| Gross Profit | $483.40M | $423.08M | $407.94M | - | $402.18M | $391.40M | $338.83M | - | $341.41M | $310.39M |
| R&D | $449.05M | $399.87M | $356.01M | - | $384.61M | $304.25M | $297.66M | - | $459.09M | $234.86M |
| SG&A | $265.69M | $243.93M | $236.44M | - | $210.38M | $220.26M | $174.22M | - | $180.28M | $165.13M |
| Total Operating Expenses | $879.99M | $824.55M | $704.23M | - | $703.11M | $630.61M | $559.51M | - | $722.02M | $478.08M |
| D&A | - | - | $12.42M | - | - | - | $11.40M | - | - | - |
| Operating Income | ($231.34M) | ($220.72M) | ($184.51M) | - | ($192.81M) | ($133.11M) | ($133.05M) | - | ($297.96M) | ($89.60M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($571.0K) | $2.89M | $4.62M | - | $2.29M | $107.0K | $0 | - | $1.11M | - |
| Net Income | ($215.79M) | ($211.53M) | ($174.74M) | - | ($190.82M) | ($134.83M) | ($136.49M) | - | ($293.85M) | ($84.58M) |
| EPS - Basic | ($1.15) | ($1.13) | ($0.93) | - | ($1.03) | ($0.73) | ($0.74) | - | ($1.61) | ($0.47) |
| EPS - Diluted | ($1.15) | ($1.13) | ($0.93) | - | ($1.03) | ($0.73) | ($0.74) | - | ($1.61) | ($0.47) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $428.57M | $308.44M | $335.85M | $319.94M | $362.60M | $364.87M | $261.00M | $424.83M | $685.17M | $413.43M |
| Accounts Receivable | $631.55M | $586.05M | $495.78M | $501.91M | $486.75M | $438.04M | $401.01M | $389.26M | $387.17M | $379.74M |
| Inventory | $531.19M | $486.85M | $477.69M | $427.21M | $364.97M | $319.35M | $275.75M | $200.66M | $181.38M | $163.18M |
| Accounts Payable | $224.81M | $114.42M | $141.47M | $207.85M | $144.50M | $128.87M | $87.23M | $114.82M | $109.96M | $102.40M |
| Current Assets | $2.55B | $2.52B | $2.60B | $2.80B | $2.76B | $2.78B | $2.77B | $2.87B | $3.11B | $3.10B |
| Total Assets | $3.63B | $3.50B | $3.54B | $3.67B | $3.62B | $3.63B | $3.62B | $3.72B | $3.98B | $3.95B |
| Current Liabilities | $954.72M | $762.90M | $713.23M | $818.40M | $726.00M | $608.52M | $531.29M | $568.85M | $698.43M | $433.83M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $2.55B | $2.62B | $2.72B | $2.80B | $2.82B | $2.93B | $3.00B | $3.07B | $3.16B | $3.39B |
| Retained Earnings | ($2.76B) | ($2.54B) | ($2.33B) | ($2.15B) | ($2.01B) | ($1.82B) | ($1.68B) | ($1.54B) | ($1.37B) | ($1.08B) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($249.64M) | - | - | - | ($216.81M) | - | - | - |
| Investing Cash Flow | - | - | $232.34M | - | - | - | $26.66M | - | - | - |
| Financing Cash Flow | - | - | $29.94M | - | - | - | $26.66M | - | - | - |
| CapEx | - | - | $38.66M | - | - | - | $17.40M | - | - | - |
| Free Cash Flow | - | - | ($288.30M) | - | - | - | ($234.21M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 74.5% | 70.1% | 78.5% | - | 78.8% | 78.7% | 79.5% | - | 80.5% | 79.9% |
| Operating margin | -35.7% | -36.6% | -35.5% | - | -37.8% | -26.8% | -31.2% | - | -70.3% | -23.1% |
| EBITDA margin | - | - | -33.1% | - | - | - | -28.5% | - | - | - |
| Net margin | -33.3% | -35.0% | -33.6% | - | -37.4% | -27.1% | -32.0% | - | -69.3% | -21.8% |
| Free cash flow margin | - | - | -55.5% | - | - | - | -54.9% | - | - | - |
| FCF / Net income | - | - | 1.65 | - | - | - | 1.72 | - | - | - |
| R&D / Revenue | 69.2% | 66.2% | 68.5% | - | 75.4% | 61.2% | 69.8% | - | 108.3% | 60.5% |
| SG&A / Revenue | 41.0% | 40.4% | 45.5% | - | 41.2% | 44.3% | 40.9% | - | 42.5% | 42.5% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.9% | -6.1% | -4.9% | - | -5.3% | -3.7% | -3.8% | - | -7.4% | -2.1% |
| Return on equity | -8.5% | -8.1% | -6.4% | - | -6.8% | -4.6% | -4.6% | - | -9.3% | -2.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.67 | 3.30 | 3.65 | 3.42 | 3.80 | 4.57 | 5.22 | 5.04 | 4.46 | 7.14 |
| Quick ratio | 2.12 | 2.66 | 2.98 | 2.90 | 3.30 | 4.04 | 4.70 | 4.69 | 4.20 | 6.77 |
| Cash ratio | 0.45 | 0.40 | 0.47 | 0.39 | 0.50 | 0.60 | 0.49 | 0.75 | 0.98 | 0.95 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.42 | 1.33 | 1.30 | 1.31 | 1.28 | 1.24 | 1.21 | 1.21 | 1.26 | 1.17 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.18 | 0.17 | 0.15 | - | 0.14 | 0.14 | 0.12 | - | 0.11 | 0.10 |
| Inventory turnover | 0.31 | 0.37 | 0.23 | - | 0.30 | 0.33 | 0.32 | - | 0.46 | 0.48 |
| Days sales outstanding | 355d | 354d | 348d | - | 348d | 321d | 343d | - | 333d | 357d |
| Days inventory outstanding | 1173d | 983d | 1560d | - | 1232d | 1099d | 1149d | - | 801d | 763d |
| Days payable outstanding | 497d | 231d | 462d | - | 488d | 443d | 363d | - | 486d | 479d |
| Cash conversion cycle | 1032d | 1106d | 1446d | - | 1092d | 977d | 1128d | - | 649d | 641d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 27.1% | 21.4% | 21.9% | - | 20.3% | 28.1% | 28.5% | - | -60.1% | 39.7% |
| Revenue CAGR (3y) | -15.1% | 29.5% | 30.4% | - | 33.8% | 31.6% | 29.8% | - | 35.8% | 31.7% |
| Revenue CAGR (5y) | 30.8% | 28.8% | 29.9% | - | 30.4% | 35.7% | 31.3% | - | 31.9% | 32.4% |
| Gross profit growth (YoY) | 20.2% | 8.1% | 20.4% | - | 17.8% | 26.1% | 12.0% | - | -65.3% | - |
| Operating income growth (YoY) | -20.0% | -65.8% | -38.7% | - | 35.3% | -48.6% | -8.7% | - | - | 4.6% |
| Net income growth (YoY) | -13.1% | -56.9% | -28.0% | - | 35.1% | -59.4% | -12.4% | - | - | -299.1% |
| EPS growth (YoY) | -11.7% | -54.8% | -25.7% | - | 36.0% | -55.3% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -23.1% | - | - | - | -76.3% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -9.6% | -10.7% | -9.2% | -8.5% | -10.8% | -13.5% | -12.4% | -12.1% | 40.2% | 86.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$1.57B totalProduct$1.39B · 88.0%
Royalty$150.52M · 9.6%
License And Service$38.28M · 2.4%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Seagen Inc. against the 5 most active filers in the same SIC group.